Diagnostic and therapeutic challenges in the management of glandular abnormalities of the cervix

References

• Davey DD, Neal MH, Wilbur DC et al. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch. Pathol. Lab. Med.128, 1224–1229 (2004).
   PubMed Web of Science ®Google Scholar
• Sharpless KE, Peter F, Schnatz PF et al. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet. Gynecol.105, 494–500 (2005).
   PubMedGoogle Scholar
• Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA287(16), 2114–2119 (2002).
   PubMed Web of Science ®Google Scholar
• Vizcaino AP, Moreno V, Bosch FX et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer86, 429–435 (2000).
   PubMed Web of Science ®Google Scholar
• Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989–1998, decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int. J. Cancer113, 1005–1009 (2005).
   PubMed Web of Science ®Google Scholar
• Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int. J. Gynecol. Cancer11, 24–31 (2001).
   PubMed Web of Science ®Google Scholar
• Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol. Oncol.75, 55–61 (1999).
   PubMedGoogle Scholar
• Ruba S, Schoolland M, Allpress S, Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer102, 280–287 (2004).
   PubMedGoogle Scholar
• Covell JL, Wilbur DC, Guidos B, Lee KR, Chhieng DC, Mody DR. Epithelial abnormalities: glandular. In: The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria and Explanatory Notes. Solomon D, Nayar R (Eds). Springer-Verlag, NY, USA, 123–156 (2004).
   Google Scholar
• Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology prevention and the role of human papillomavirus infection. CMAJ164, 1017–1025 (2001).
   PubMed Web of Science ®Google Scholar
• Wright TC Jr, Massad LS, Dunton CJ et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am. J. Obstet. Gynecol.197(4), 340–345 (2007).
   PubMed Web of Science ®Google Scholar
• Levine L, Lucci JA 3rd, Dinh TV. Atypical glandular cells: new bethesda terminology and management guidelines. Obstet. Gynecol. Surv.58, 399–406 (2003).
   PubMedGoogle Scholar
• Cangiarella JF, Chhieng DC. Atypical glandular cells – an update. Diagn. Cytopathol.29, 2 (2003).
   Google Scholar
• Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet. Gynecol.115(2 Pt 1), 243–248 (2010).
   PubMed Web of Science ®Google Scholar
• Syrjanen K. Is improved detection of adenocarcinoma in situ by screening a key to reducing the incidence of cervical adenocarcinoma? Acta Cytol.48, 591–594 (2004).
   PubMedGoogle Scholar
• Tam KF, Cheung AN, Liu KL et al. A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol. Oncol.91, 603–607 (2003).
   PubMed Web of Science ®Google Scholar
• Westin MC, Derchain SF, Rabelo-Santos SH et al. Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications. Eur. J. Obstet. Gynecol. Reprod. Biol.139, 79–85 (2008).
   PubMed Web of Science ®Google Scholar
• Castellsague X, Diaz M, de Sanjose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl Cancer Inst.98, 303–315 (2006).
   PubMed Web of Science ®Google Scholar
• Demay RM. The pap smear. In: The Art and the Science of Cytopathology. ASCP Press, Chicago, IL, USA, 61–185 (1996).
   Google Scholar
• Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer99, 336–341 (2003).
   PubMed Web of Science ®Google Scholar
• Verdiani LA, Derchain SFM, Schweller M, Gontijo RC, Angelo-Andrade LA, Zeferino LC. Atypical glandular cells in cervical smear: analysis of diagnostic methods. Rev. Bras. Ginecol. Obstet.25, 193–200 (2003).
   Google Scholar
• Derchain SF, Rabelo-Santos SH, Sarian LO et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol. Oncol.95, 618–623 (2004).
   PubMedGoogle Scholar
• Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int. J. Gynecol. Cancer11, 24–31 (2001).
   PubMed Web of Science ®Google Scholar
• Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix. A case–control study. Acta Cytol.489, 595–600 (2004).
   Google Scholar
• Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am. J. Obstet. Gynecol.197, 566–571 (2007).
   PubMedGoogle Scholar
• Lehtovirta P, Finne P, Nieminen P et al. Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women – a long term follow-up study in a low prevalence population. Int. J. STD AIDS17, 831–834 (2006).
   PubMedGoogle Scholar
• Massad LS, Xie X, Darragh TM et al. Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet. Gynecol.114(5), 1063–1068 (2009).
   PubMedGoogle Scholar
• de Sanjose S, Quint WG, Alemany L et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol.11(11), 1048–1056 (2011).
   Google Scholar
• Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111, 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: international biological study on cancer (IBSCC) study group. J. Natl Cancer Inst.87, 796–802 (1995).
   PubMed Web of Science ®Google Scholar
• Andersson S, Rylander E, Larson B et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol. Rep.10, 175–179 (2003).
   PubMedGoogle Scholar
• Pirog EC, Kleter B, Olgac S et al. Prevalence of HPV-DNA in different histologic subtypes of cervical adenocarcinoma. Am. J. Pathol.157, 1055–1062 (2000).
   PubMed Web of Science ®Google Scholar
• Rabelo-Santos SH, Derchain SFM, Villa LL et al. Human papillomavirus-specific genotypes in cervical lesions of women referred for smears with atypical glandular cells or adenocarcinoma in situ. Int. J. Gynecol. Pathol.28, 272–278 (2009).
   PubMedGoogle Scholar
• Zhao C, Chen X, Onisko A, Kanbour A, Austin RM. Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecol. Oncol.122(2), 291–296 (2011).
   PubMedGoogle Scholar
• Burk RD, Masanori T, Gravitt PE et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res.63, 7215–7220 (2003).
   PubMedGoogle Scholar
• De Boer MA, Peters LA, Aziz MF et al. Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands. Gynecol. Oncol.94, 488–494 (2004).
   PubMedGoogle Scholar
• Tornesello ML, Duraturo ML, Salatiello I et al. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J. Med. Virol.74, 117–126 (2004).
   PubMedGoogle Scholar
• Berumen J, Ordonez RM, Lazcano E et al. Asian–American variants of human papillomavirus 16 and risk for cervical cancer: a case–control study. J. Natl Cancer Inst.93, 1325–1330 (2001).
   PubMedGoogle Scholar
• Lizano M, Berumen J, Guido M, Casas L, Garcia-Carranca A. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J. Natl Cancer Inst.89, 1227–1231 (1997).
   PubMedGoogle Scholar
• De Boer MA, Peters LA, Aziz MF et al. Human papillomavirus type 18 variants: histopathology and E6/E7 polymorphisms in three countries. Int. J. Cancer114, 422–425 (2005).
   PubMedGoogle Scholar
• Villa LL, Sichero L, Rahal P et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J. Gen. Virol.81, 2959–2968 (2000).
   PubMed Web of Science ®Google Scholar
• Rabelo-Santos SH, Villa LL, Derchain SF et al. variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. Int. J. Gynecol. Pathol.25, 393–397 (2006).
   PubMedGoogle Scholar
• Madeleine MM, Daling JR, Schwartz SM et al. Human papillomavirus and longterm oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol. Biomarkers Prev.10, 171–177 (2001).
   PubMedGoogle Scholar
• Widrich T, Kennedy AW, Myers TM, Hart WR, Wirth S. Adenocarcinoma in situ of the uterine cervix: management and outcome. Gynecol. Oncol.61, 304–308 (1996).
   PubMedGoogle Scholar
• Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA287, 2120–2129 (2002).
   PubMed Web of Science ®Google Scholar
• Rabelo-Santos SH, Angelo-Andrade LA, Derchain SF, Oliveira ER, Sarian LO, Westin MC. Endocervical glandular cell abnormalities in conventional cervical smears: cytomorphologic criteria and HPV test for the prediction of glandular neoplasia. Cytopathology19, 34–43 (2008).
   PubMedGoogle Scholar
• Oliveira ER, Derchain SF, Rabelo-Santos SH et al. Detection of high risk human papillomavirus (HPV) DNA by Hybrid Capture II in women referred due to atypical glandular cells in the primary screening. Diagn. Cytopathol.31(1), 19–22 (2004).
   PubMedGoogle Scholar
• Krane JF, Lee KR, Sun D, Yuan L, Crum CP. Atypical glandular cells of undetermined significance. Outcome predictions based on human papillomavirus testing. Am. J. Clin. Pathol.121, 87–92 (2004).
   PubMed Web of Science ®Google Scholar
• Irvin W, Evans SR, Andersen W et al. The utility of HPV DNA triage in the management of cytological AGC. Am. J. Obstet. Gynecol.193(2), 559–565 (2005).
   PubMedGoogle Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F et al.; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol.11(3), 249–257 (2010).
   PubMed Web of Science ®Google Scholar
• Sharpless KE, O’Sullivan DM, Schnatz PF. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. J. Low Genit. Tract. Dis.13(2), 72–78 (2009).
   PubMedGoogle Scholar
• Schnatz PF, Sharpless KE, O’Sullivan DM. Use of human papillomavirus testing in the management of atypical glandular cells. J. Low Genit. Tract. Dis.13(2), 94–101 (2009).
   PubMedGoogle Scholar
• Chen L, Yang B. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer114, 236–241 (2008).
   PubMedGoogle Scholar
• Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet. Gynecol.115(2 Pt 1), 243–248 (2010).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J. Natl Cancer Inst.103(5), 368–383 (2011).
   PubMedGoogle Scholar
• Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am. J. Obstetrics Gynecol.197, 566–571 (2007).
   PubMedGoogle Scholar
• Ries L, Harkins D, Krapcho M et al. SEER cancer statistics review, 1975–2004, National Cancer Institute, Bethesda, MD, USA, based on November 2005 SEER data submission (2007).
   Google Scholar
• Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups. Cancer69, 1291–1299 (2000).
   Google Scholar
• Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet357, 1490–1493 (2001).
   PubMed Web of Science ®Google Scholar
• Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM. Decreasing incidence of cervical adenocarcinoma in Ontario: is this related to improved endocervical Pap test sampling? Int. J. Cancer120, 362–367 (2006).
   Google Scholar
• Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer103, 1258–1264 (2005).
   PubMed Web of Science ®Google Scholar
• Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol. Oncol.59, 38–44 (1995).
   PubMed Web of Science ®Google Scholar
• Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol. Oncol.86, 365–369 (2002).
   PubMedGoogle Scholar
• Costa S, Negri G, Sideri M et al. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol. Oncol.106, 170–176 (2007).
   PubMedGoogle Scholar
• Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH. The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. Eur. J. Obstet. Gynecol. Reprod. Biol.145(1), 100–103 (2009).
   PubMedGoogle Scholar
• Cohn DE, Morrison CD, Zanagnolo VL, Goist MM, Copeland LJ. Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. Gynecol. Oncol.98, 158–160 (2005).
   PubMedGoogle Scholar
• Soutter WP, Haidopoulos D, Gornall RJ et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG108, 1184–1189 (2001).
   PubMedGoogle Scholar
• Young JL, Jazaeri AA, Lachance JA et al. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am. J. Obstet. Gynecol.197, 195.e1–7; discussion 195.e7–8 (2007).
   Google Scholar
• Mestwerdt G. The early diagnosis of cervical carcinomas. Zentralbl Gynakol.69, 198–202 (1947).
   Google Scholar
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet.105, 103–104 (2009).
   PubMed Web of Science ®Google Scholar
• Tamimi HK, Figge DC. Adenocarcinoma of the uterine cervix. Gynecol. Oncol.13, 335–344 (1982).
   PubMedGoogle Scholar
• Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. Gynecol. Oncol.107, 424–430 (2007).
   PubMed Web of Science ®Google Scholar
• Ceballos KM, Shaw D, Daya D. Microinvasive cervical adenocarcinoma (FIGO stage IA tumors): results of surgical staging and outcome analysis. Am. J. Surg. Pathol.30, 370–374 (2006).
   PubMedGoogle Scholar
• Reynolds EA, Tierney K, Keeney GL et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet. Gynecol.116(5), 1150–1157 (2010).
   PubMedGoogle Scholar
• Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55, 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• Jaworski RC, Pacey NF, Greenberg ML, Osborn RA. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri: adenocarcinoma in situ. Cancer61, 1171–1181 (1988).
   PubMedGoogle Scholar
• Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int. J. Gynecol. Pathol.21, 314–326 (2002).
   PubMed Web of Science ®Google Scholar
• Baalbergen A, Ewing-Graham PC, Hop WCJ, Struijk P, Helmerhorst TJM. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol. Oncol.92, 262–267 (2004).
   PubMed Web of Science ®Google Scholar
• Shimada M, Kiwaga J, Nishimura R et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol. Oncol.101, 234–237 (2006).
   PubMed Web of Science ®Google Scholar